Demystifying the Evolving Science and Potential Role of Incretins in T2D In this episode, Kristin Gusack, RD will interview Bernhard Ludvik, MD and Thomas Forst, MD.  They will discuss the practical application of data and frequently asked questions from the independent satellite symposium, Demystifying the Evolving Science and Potential Role of Incretins in T2D, presented at IDF World Diabetes Congress on December 6, 2022. Click Here to Take this Activity for Credit! Or just listen

Clinical Perspectives on Dual Checkpoint Blockade for mNSCLC Dual checkpoint blockade is becoming a more common approach for patients with mNSCLC and no targetable driver mutation, and a new regimen was recently approved. Join us to hear from a thoracic oncologist, Christine Bestvina, MD, about how these regimens are changing patients’ perspectives about their likely outcomes, the clinical implications of emerging safety and efficacy data, and how to educate patients about participating in clinical trials.

Potential Benefits of Incretins Beyond Glycemic Control in T2D In this episode, Kristin Gusack interviews Dr. Juan Frias and Dr. Stefano Del Prado.  They discuss the practical application of data and frequently asked questions from the independent satellite symposium, Potential Benefits of Incretins Beyond Glycemic Control in T2D, presented at EASD on September 19, 2022. Click Here to Take this Activity for Credit! Or just listen to the episode using the player below: